Mechanical Cardiac Support 2000: Current applications and future trial design June 15-16, 2000, Bethesda, Maryland by Stevenson, Lynne Warner & Kormos, Robert L.
418
WALTER E. PAE, JR, MD, FACC
GEORGE PANTALOS, PhD
D. GLENN PENNINGTON, MD, FACC
ERIC A. ROSE, MD, FACC
JOHN T. WATSON, PhD
JAMES T. WILLERSON, MD, FACC
JAMES B. YOUNG, MD, FACC
ROBERT C. BOURGE, MD, FACC
ANNETINE GELIJNS, PhD
BARTLEY P. GRIFFITH, MD
RAY E. HERSHBERGER, MD, FACC
SHARON HUNT, MD, FACC
JAMES KIRKLIN, MD, FACC
LESLIE W. MILLER, MD, FACC
CONSENSUS CONFERENCE REPORT
MECHANICAL CARDIAC SUPPORT 2000: CURRENT APPLICATIONS AND FUTURE TRIAL DESIGN
June 15-16, 2000
Bethesda, Maryland
Lynne Warner Stevenson, MD, FACC, Conference Co-Chair
Robert L. Kormos, MD, Conference Co-Chair
STEERING COMMITTEE MEMBERS
WRITING GROUP PARTICIPANTS
MARK L. BARR, MD 
MARIA ROSA COSTANZO, MD, FACC 
PATRICE DESVIGNE-NICKENS, MD 
ARTHUR MICHAEL FELDMAN, MD, PhD, FACC 
O. HOWARD (BUD) FRAZIER, MD, FACC 
LAWRENCE FRIEDMAN, MD 
J. DONALD HILL, MD, FACC 
MARVIN A. KONSTAM, MD, FACC 
PATRICK McGUANE McCARTHY, MD
ROBERT E. MICHLER, MD, FACC
MEHMET C. OZ, MD, FACC 
BRUCE R. ROSENGARD, MD 
WOLF SAPIRSTEIN, MD 
RHONA SHANKER 
CRAIG R. SMITH, MD 
RANDALL C. STARLING, MD, MPH, FACC 
DAVID O. TAYLOR, MD, FACC 
ALISON WICHMAN, MD
INVITED REPRESENTATIVES OF INDUSTRY
DALLAS W. ANDERSON 
KEN CHARHUT 
LAURA DAMME, RN, MPH 
MICHAEL R. DEVRIES
LORENZO DICARLO, MD, FACC
DAVID J. FARRAR, PhD
LEONARD A. R. GOLDING, MD, FACC
STEVEN A. KOLENIK 
TIM KRAUSKOPF 
DOUGLAS McNAIR, MD, PhD
TOFY MUSSIVAND, PhD
CHISATO NOJIRI, MD, PhD
GEORGE P. NOON, MD 
STEVEN J. PHILLIPS, MD, FACC 
PEER M. PORTNER, PhD, FACC 
ERIC SCHORSCH 
JOSEPH J. SCHWOEBEL, MBA 
WINSTON UMEMURA
ROBERT L. WHALEN, PhD
HELENE ZINTAK, PA
J Thorac Cardiovasc Surg 2001;121:418-24
Copyright © 2001 by the American College of Cardiology
Reprinted with permission of the American College of Cardiology.
12/1/113857
doi:10.1067/mtc.2001.113857
The Journal of Thoracic and
Cardiovascular Surgery
Volume 121, Number 3
Stevenson and Kormos 419
Sponsoring organizations
The conference was conducted with financial and other
support from the following organizations: American College
of Cardiology, American Heart Association, International
Society for Heart and Lung Transplantation, American
Society of Transplantation, Heart Failure Society of America,
The American Association for Thoracic Surgery, the Society
of Thoracic Surgeons, and the American Society of
Transplant Surgeons.* Additionally, participants included
members of these agencies: Food and Drug Administration,
National Institutes of Health, and the American Society for
Artificial Internal Organs. 
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Impact statement
Heart failure presents an increasing public health burden
of morbidity and mortality even as the mortality from coro-
nary artery disease and hypertension is decreasing. While
effective pharmacologic therapies have improved outcomes
for mild-moderate heart failure, the impact of newer thera-
pies and mechanical circulatory support for advanced heart
failure has not yet been realized. Implantable devices have
been shown to be safe and effective as bridges to cardiac
transplantation, but further work is needed to establish the
role of mechanical support for myocardial recovery and for
long-term support. This conference was held to assess current
mechanical support applications and future trial designs for
investigation affecting this public health issue.
The participants concluded that important differences
between devices and drugs may warrant novel study designs
characterized by innovation and flexibility. While the ran-
domized clinical trial remains the most powerful tool for
unambiguous comparison of interventions, variations may
include timed graduation from control to investigational ther-
apies, assignment influenced by patient risk or patient pref-
erences and criteria for an optional crossover to compas-
sionate device use. A major impact would result from a
national outcomes database for advanced heart failure that
identifies high-risk populations with the greatest potential for
benefit from newer therapies and thus facilitates the design of
devices and device trials. A separate registry with industry of
outcomes after device placement would help to identify
“breakthrough” device therapies and facilitate the refinement
and acceptance of this new technology. As represented in this
conference, progress in mechanical circulatory support will
be accelerated by the continued coordination of scientists,
engineers, industry, clinical investigators and regulatory and
payment agencies in prospective partnership.
Introduction
Over the past five years, mechanical circulatory sup-
port devices have evolved from the earlier investiga-
tional stages to become standard therapy for bridging
to transplantation, in some cases extending beyond
original indications. As the first randomized controlled
trial of mechanical circulatory support, the Ran-
domized Evaluation of Mechanical Assistance in the
Treatment of Congestive Heart Failure (REMATCH)
trial began in 1998 and has undergone regular protocol
modifications resulting from experiences gained with
the patient population and the devices themselves. In
1999, an expert review panel for the National Heart,
Lung, and Blood Institute (NHLBI) recommended con-
tinued support for the development of total artificial
heart programs. Refinement of currently available left
ventricular (LV) devices continues steadily, and many
new types of support devices are in or approaching
clinical trials. Ethical and practical issues have
emerged regarding the design and funding of these
future clinical trials. Challenges for optimal application
are being compounded as the separation between indi-
cations for recovery, bridge to transplantation and per-
manent use is becoming less distinct.
As in the original conference on trial design for
mechanical circulatory support led by Pae in 1995, the
goals of investigators, governmental agencies and
industry remain the establishment of clinical trials that
are “scientifically sound, clinically meaningful and
achievable in a finite time frame at reasonable
expense.” With the rapid increase in experience with
populations of advanced heart failure, broader clinical
application of available devices and the promise of new
technology for future support, members of the steering
group for the NHLBI, the Food and Drug
Administration (FDA), the American College of
Cardiology Committee on End-Stage Heart Failure and
the International Society for Heart and Lung
Transplantation sought broad representation from pro-
fessional societies and industry to address the issues
involved in trial design for mechanical circulatory sup-
port looking ahead from 2000.
The professional societies with significant interest in
this field were invited to co-sponsor this conference
and to select delegates to participate in the discussion
and writing of the draft document. The writing groups
established the basis of their conclusions for discussion
*The recommendations set forth in this report are those of the con-
ference participants and do not necessarily reflect the official posi-
tion of the American College of Cardiology. The full text document
will be published in the Journal of the American College of
Cardiology and the Journal of Heart and Lung Transplantation, and
the executive summary will be published in Circulation and the
Journal of Thoracic and Cardiovascular Surgery. This document is
available on the World Wide Web site of the American College of
Cardiology (www.acc.org). Reprints of this document are available
for $5.00 each by calling 800-253-4636 (U.S. only) or by writing the
Resource Center, American College of Cardiology, 9111 Old
Georgetown Road, Bethesda, Maryland 20814.
and subsequent revision by all participants during the
conference at the Heart House in Bethesda, Maryland,
to which representatives of industry were also invited.
The published document represents the consensus of
the participants, as approved by the Steering
Committee, and does not imply formal acceptance by
any of the societies represented. New developments
will render the specifics of this document obsolete, but
it is hoped that the fundamental considerations estab-
lished here will help to guide trial design and clinical
decisions for the near future.
Executive summary
Present status of devices for heart failure. Current
use of mechanical circulatory support devices is domi-
nated by the indications of post-cardiotomy shock and
bridging to cardiac transplantation. In the U.S., about
6,000 patients a year receive support devices after car-
diac surgery, with hospital survival of 20% to 40%.
Sustained improvement of native heart function after
support also occurs in 5% to 15% of transplant candi-
dates, with greater frequency of recovery in patients
with fulminant myocarditis. Bridging to cardiac trans-
plantation occurs in 300 to 400 patients yearly in the
U.S., with an overall discharge rate of 50% to 70%
from device implantation through transplantation.
Limitations in our current conception of device indi-
cations need to be recognized. First, the need for biven-
tricular versus univentricular support is difficult to
determine. Second, the ultimate utility of a total artifi-
cial heart versus ventricular assist device(s) (VAD) has
not been established. Third, the intended duration of
mechanical support is a moving target. The time and
type of device utilization is influenced by external fac-
tors such as the time to myocardial recovery, donor
organ availability, the potential of outpatient therapy
and the unpredictability of adverse events associated
with new technology. Thus, even within the field of
currently used devices, evolving indications mandate
flexible guidelines for utilization.
Development of drugs and surgical devices for
advanced heart failure. Observation provided the
basis for early therapies of heart failure, many of which
have subsequently been abandoned. A systematic
approach to testing pharmacologic therapies in heart
failure has arisen only within the last 20 years. The
basis of evidence supporting the current medical thera-
py with angiotensin-converting enzyme inhibitors and
beta-adrenergic receptor antagonists has arisen from
double-blind, randomized controlled trials in hundreds
to thousands of patients with mild to moderate heart
failure. Except for digoxin, oral inotropic agents have
been shown in controlled trials to increase mortality,
despite sound theoretical rationale. The template of the
double-blind, randomized control trial has emerged as
the gold standard for evaluating new pharmacologic
therapies. It has not been applied to urgent therapies
such as diuretics for relief of pulmonary edema and
intravenous inotropic agents for cardiogenic shock
(CS), during which placebo therapies might be regard-
ed as unacceptable.
Many surgical approaches have been introduced for
heart failure. The coronary artery surgery trial demon-
strated benefit in patients with reduced left ventricular
ejection fractions (LVEFs) but did not target patients
with symptomatic heart failure. Requiring five years to
complete enrollment, the trial of revascularization for
acute CS demonstrated benefit in patients <75 years of
age. Revascularization, valve surgery and other remod-
eling techniques are being employed for some patients
with more severe chronic heart failure (HF). The inabil-
ity to provide comparable placebo therapy, strong
patient preferences regarding invasive procedures, and
the front-loaded risk of operative procedures have com-
plicated the evaluation of these new approaches.
Fundamental differences between drugs and devices.
As therapies for heart failure advance beyond drugs
into procedures and devices, fundamental differences
emerge in the evaluation of efficacy. By contrast with
drug development, progress with devices is more incre-
mental, with experience leading to progressive device
modifications. The impact of devices is more transpar-
ent, in part because the most obvious risks are front-
loaded compared with those from new drugs. It is hard-
er for the effects of devices to be masked or mimicked
by the natural history of heart failure. Practical consid-
erations relate to the higher order of magnitude of
expense per patient in a trial, which can be prohibitive
for companies without major revenue from previous
products. The clinically meaningful benefit, however,
is projected to be larger than the benefit of new drugs,
such that estimated sample sizes are in hundreds rather
than thousands of subjects. The experience and skill
necessary to achieve optimal outcomes restrict center
participation in trials and limit the generalizability of
results. A crucial difference between drugs and devices
is the inability to blind patients or physicians to thera-
py, a limitation with both ethical and practical implica-
tions for clinical trials.
The sum of evidence guiding therapy with drugs is
dominated by evidence from large trials completed
prior to drug approval. Once it is approved, it is diffi-
cult to identify use and attribute effects of any particu-
lar drug because of variable prescription, adherence
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and combination with other medications. For this rea-
son, post-marketing surveillance provides limited
information regarding drugs for heart failure, except for
non-cardiovascular side effects. By contrast, the very
complexity and undisguised impact of devices render
their use and outcomes easier to track, as long as appro-
priate registries are maintained. The cumulative body
of evidence guiding the ultimate use of devices may be
drawn more from information gained after initial
approval.
Target populations and end points for mechanical
circulatory support. Target populations for mechani-
cal circulatory support can be defined by the expected
natural history of heart failure. Patients with CS have
an in-hospital mortality of >50% but also carry high
risk for patient-related operative complications.
Ambulatory patients without resting symptoms on stan-
dard oral therapy often survive for two years or longer.
Despite various approaches to risk stratification, it
remains hard to specify an intermediate-risk popula-
tion. For patients receiving outpatient intravenous
inotropic therapy, the six-month mortality is currently
in the range of 50%. However, without objective indi-
cations for and restrictions on this therapy, it may
encroach on the population with less advanced disease.
Another target population might be cardiac transplant
patients with triple vessel coronary artery disease
(CAD) and decreased ejection fraction, with <50%
one-year survival, but mechanical devices in the post-
transplant population may be complicated by previous
surgery and immunosuppression. The target population
for trials should be defined widely to include patients
with the best natural history compatible with the degree
of certainty that a given device will provide an
improvement. This would be greatly facilitated by a
multicenter registry of advanced heart failure. After
approval, ongoing re-evaluation of a successful device
should reflect the observed trend for downshifting
risks, in which procedures with proven benefit in a
high-risk population become generalized to patients
with less risk of post-operative complications but
potentially less benefit.
End points for clinical trials will be chosen according
to the severity of disease in the population selected. For
patients with the most severe disease, early survival
will be a fundamental end point. A combination of
early survival and functional end points may be most
appropriate for trials allowing eventual device place-
ment in patients randomized to medical therapy. As the
risk of death becomes imminent, measurements of
functional capacity, quality of life and survival adjust-
ed for patient preferences become increasingly rele-
vant. At all levels, measures of efficacy will need to be
supplemented by measures of cost-effectiveness. It
Fig 1.  Line depicting the relationship between equipoise and efficacy of a new therapy, as perceived after initial
clinical testing. It is possible that the early experience could be so dramatic that both the scientific and regulatory
community regard it as a “breakthrough” therapy that should be approved without further investigation for the
defined population. Initial experience could also demonstrate sufficient success that the scientific community is
convinced of efficacy, while the regulatory agencies require further information. This gap might be bridged by con-
tinued clinical investigation at limited sites, with prospective definition of a non-randomized cohort for compari-
son. In the majority of cases, initial testing does not establish efficacy, and clinical equipoise can be maintained for
the performance of randomized controlled trials. It is anticipated that patient preference regarding new therapies
will most often lie to the right of clinical equipoise, complicating trials of therapies that cannot be blinded. The
asymmetry of the line to the right of equipoise reflects the enthusiasm necessary to drive any therapy through clin-
ical evaluation.
should be emphasized, however, that cost-effectiveness
for a successful device is likely to improve after
approval, as experience is gained and costs are
decreased.
The spectrum including “breakthrough” devices.
In the future, initial studies could identify a therapy
with such an obvious impact on survival that it would
be considered a “breakthrough” for a population with
otherwise high early mortality (Fig 1). In retrospect,
cardiac transplantation was considered a breakthrough
that has been widely accepted without a controlled
study. Most new therapies do not enter the break-
through realm during preliminary testing but fall some-
where else along the spectrum before approval. Outside
of breakthroughs, there may be some therapies that are
not yet approved but are considered by experienced
clinicians to be so effective that waiting for a controlled
trial would not be ethical. The best way to bridge this
gap to expedite approval from regulatory agencies has
not yet been determined for any of the life-threatening
diseases. The focus of this conference is not on the
approval process but on designing trials of devices for
which there is reasonable doubt regarding efficacy.
Even for devices in the breakthrough realm for end-
stage disease, the design of trials would remain relevant
for extension to those populations with lesser severity
of illness, in whom the benefit of the device could not
be assumed.
Trial design for mechanical circulatory support.
All new devices are required by the Medical Device
Amendments Act to be “safe and effective,” as shown
through “well-controlled scientific studies” or “valid
scientific evidence.” Because mechanical circulatory
support devices fall into the highest of three risk cate-
gories, the sponsor must conduct clinical trials before
the FDA grants a pre-marketing approval (PMA) deci-
sion. Multiple challenges characterize the performance
of these trials for mechanical support devices. Because
device innovation, exemplified by left ventricular assist
devices (LVADs), is incremental and iterative, it is dif-
ficult to determine when a device should come to clin-
ical trial and which aspects of development should be
“frozen” while modification continues throughout the
investigational and post-marketing stages. There is lit-
tle precedent for trial design when a high severity of ill-
ness limits the duration of observation and humanistic
concerns dictate consideration of alternate therapies
outside protocol. Other life-threatening illnesses, such
as cancer and AIDS, have led to consideration of
research designs to minimize ethical conflicts and
shorten the PMA processes while shifting more empha-
sis to rigorous post-marketing studies.
The randomized controlled trial (RCT) remains
widely regarded as the most powerful and sensitive tool
for comparing therapeutic interventions and the most
persuasive force for the acceptance of new technology.
Many of the differences between drugs and devices, as
detailed in the preceding text, complicate the transla-
tion of RCTs from pharmaceutical trials to trials of
mechanical support devices. 
Ethics of randomized controlled trials for mechanical
circulatory support.  Special emphasis was placed by
this conference on consideration of the ethics of RCTs
for mechanical support devices. A fundamental tenet of
the ethical RCT is that equipoise exists for the treat-
ment being tested; it would thus not be ethical to do an
RCT of a device already determined from initial testing
to be in the breakthrough realm for the population
being considered. Theoretical equipoise, in which
available data and investigator preference are exactly
balanced, may in fact never be located for the individ-
ual clinician. Clinical equipoise, in which genuine
debate and uncertainty exist among the clinical com-
munity, is more feasible and relevant. Although it was
initially challenged for the REMATCH trial, the posi-
tion of equipoise was strengthened by the analysis of
pilot data from the pilot trial for REMATCH (PRE-
MATCH), in which no clear survival benefit from the
LVAD could be seen at three months. 
After randomization has taken place, the patient and
his physician are aware of the selected therapy, unlike
participation in the placebo arm of a double-blinded
drug trial. The combination of life-threatening disease
and unblinded therapy raises ethical issues beyond that
of physician equipoise at the start of the trial. The visi-
ble impact of the device may threaten maintenance of
equipoise for investigators following patients during
the course of a trial. Responding as individuals to unfil-
tered information, patients are less likely to be in posi-
tions of equipoise even before randomization. Patients
consenting to new trials are likely to be already biased
toward the procedure and thus may perceive random-
ization to the control arm as a loss of hope, with poten-
tially deleterious impacts on individual outcomes. 
Practical issues of randomized controlled trials for
mechanical circulatory support. Patient preference for
specific therapies perceived to be life-saving may limit
enrollment, particularly when a similar therapy is per-
ceived to be offered by other routes. From a method-
ologic aspect, randomization does not eliminate evalu-
ation bias when all parties know the treatment received.
Patient dissatisfaction regarding treatment choice
threatens compliance with follow-up and increases the
likelihood of off-protocol therapy that could compro-
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mise the trial results, as was seen in early trials of AZT
for AIDS. 
The cost of initiating a randomized trial for a new
device greatly exceeds that of continuing to report
uncontrolled experience. For this effort to be undertak-
en, the ultimate value in terms of acceptance as an
effective device must be consistently endorsed.
Financial impediments have profoundly impaired the
conduct of clinical trials of devices, for which there
have been substantial unreimbursed costs. These disin-
centives to enrollment increase the duration and overall
cost of the study, delaying the time to potential recov-
ery of development costs. Government support for
reimbursement of routine Medicare treatment costs and
“conditional coverage” of treatment costs in recog-
nized scientifically-designed trials are strongly
endorsed by this conference. 
Despite a number of obstacles, an RCT of classical
design is nearing completion to determine the impact
of an implantable mechanical circulatory support
device as destination therapy compared with optimal
medical therapy. If the REMATCH trial proves a sur-
vival benefit for devices in this population, similar
devices may be tested against this benchmark.
Regardless of the outcome of this trial, both the lessons
learned during its conduct and the ultimate results will
have a profound influence on the design of future trials. 
Modifications of the randomized controlled trial for
mechanical cardiac support. It should be recognized
that the gold standard methodology for evaluating the
impact of a treatment on outcome remains the random-
ized, double-blinded, placebo-controlled trial. It should
also be recognized, however, that surgical interventions
in advanced illness may not appropriately lend them-
selves to all aspects, such as blinding, of this method-
ological gold standard. With increasing appreciation
for the unique aspects of mechanical circulatory sup-
port for advanced heart failure, variations in the design
of randomized trials merit consideration. 
The aspects of randomization and a control arm can
be retained in a nonblinded trial with an option to
receive active device therapy as “compassionate use”
after the achievement of a predefined time or interme-
diate end points. (Because only the original cohorts
would be compared, this does not represent a true
crossover design.) This feature may encourage recruit-
ment and retention, while re-aligning incentives for the
patient and physician to continue full efforts after ran-
domization to a control arm. Models for randomized
trials that allow some degree of patient preference
could improve recruitment and patient satisfaction
while providing more information on outcomes for
patients not desiring device therapy. The degree to
which patient preference should influence the choice of
therapy remains a major ethical issue for this and other
life-threatening conditions. From a more practical
standpoint, it is not clear to what extent the advantages
of design modifications would outweigh the increase in
sample size that would be required. 
Comparison of non-randomized cohorts. In the
absence of a randomized control group, there are no
large historical groups that could be considered for
comparison. Contemporary cohort studies offer better
information than observational reports without com-
parison, but they are compromised by a major bias in
favor of new treatments. Data provided by a cohort
analysis of the bridge-to-transplant experience indi-
cated a major benefit from the device for that indica-
tion. While these cohort data were often cited to sug-
gest that a randomized trial of therapy in
non-transplant candidates was not ethical, its rele-
vance to this different population was questioned
when the small randomized pilot trial indicated no
major difference in early outcomes between the
device and optimal medical therapy. 
Alternatively, to generate prospective control groups,
cohortscould be defined by an obligatory control peri-
od prior to enrollment that could provide short-to-inter-
mediate-term information, after which, however, sub-
jects entering surgery might be either better or worse
than at initial evaluation. Comparison of patients pre-
ferring surgery to patients preferring medical therapy
would require an extensive adjustment for baseline fac-
tors influencing outcome, not all of which can be iden-
tified. For non-randomized cohorts, it is not possible to
adjust for all of the factors that lead to the provision of
a therapy to one patient and not another. A different
approach to outcomes adjusted for severity of illness is
being investigated for therapy of breast cancer, in
which therapy is allocated only to the patients at high-
est risk, whose outcome is then compared with that
projected from a less compromised population on stan-
dard therapy, according to a mathematical model. This
technique and all of the regression models used to con-
trol for cohort differences would require a deeper
knowledge of risk profiles and outcomes for advanced
heart failure than that which currently exists. 
Vital role of registries. The absence of broad-based
data and the magnitude of mortality, morbidity and
resource utilization argue strongly for the creation of a
registry of advanced heart failure. Such a multicenter
registry would advance both risk stratification for out-
come prediction and the development of a multivariate
regression model to help adjust for differences between
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Assist System (IVAS), the Jarvik 2000 IVAS and the
DeBakey/Micromed IVAS. These systems also depend
on transcutaneous power transmission but eliminate the
need for volume compensation. The AB-180
Circulatory Support System, the HeartMate III LVAD
and the CorAide are devices based on centrifugal prin-
ciples. In many ways our limited understanding of the
impact of this latter group of devices may dictate newer
study design principles.
Although there are no specific standards for the pre-
clinical evaluation of newer mechanical circulatory
support systems, guidelines do exist. A Preliminary
Draft Guidance for Ventricular Assist Devices and
Total Artificial Hearts issued by the FDA in December
1987 needs to be updated. The joint paper developed by
the American Society for Artificial Internal Organs
(ASAIO) and the Society of Thoracic Surgeons (STS)
addresses only reliability concerns for long-term
devices and does not address emerging technology for
which a comprehensive standard with criteria for pre-
clinical testing is still needed. The revision of these
guidelines becomes even more important as distinc-
tions between short-, intermediate- and long-term sup-
port become increasingly blurred during clinical appli-
cation. An interdisciplinary effort needs to address the
development of a comprehensive standard for the pre-
clinical evaluation of blood pumps, taking into account
the uniqueness of each system and its intended use, yet
remaining sufficiently flexible to incorporate new clin-
ical experience.
As the field moves ahead, it has become clear that no
one trial design or set of standards will be ideal or
appropriate for all of these devices, populations and
stages of development. This document represents both
consensus and controversy from leading scientists,
clinical investigators, representatives of industry and
regulatory agencies. One of the most important
achievements of this conference may be the recognition
that the pace of real progress in mechanical circulatory
support will be accelerated by ongoing collaboration. 
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cohorts. Greater confidence in our ability to identify
high-risk populations would sharpen trial design and
accelerate recognition of devices in the breakthrough
realm. Design of RCTs would be streamlined by better
selection of target populations and better prediction of
event rates.
There is now broad consensus that responsible
progress in the field of mechanical circulatory support
requires the establishment and maintenance of a
mandatory registry that includes all implantable
devices, both before and after approval. It should be
possible to require specific baseline data collection on
patients with mechanical assist devices after device
approval if that stipulation is formally linked to the ini-
tial approval. By contrast to pharmaceutical therapies,
which are easier to study before approval and harder to
track afterward, mechanical circulatory support devices
may, with appropriate registry documentation, be sup-
ported by a weight of evidence distributed differently
between pre- and post-approval experiences. 
The near future. The lessons learned through the
use of current technology have led to formative strate-
gies regarding the timing of implantation, rehabilitative
potential and discharge management in patients sup-
ported with circulatory assist devices. However, limita-
tions of systems requiring external power sources con-
nected through percutaneous drivelines have led to the
development of numerous systems that are as com-
pletely implanted in the body as possible. This has
resulted in developments along two broad approaches.
The first is a refinement of implantable pulsatile sys-
tems, including the Abiomed and Penn State/3M total
artificial hearts, the Thoratec IVAD, the Novacor II, the
World Heart Heartsaver VAD and the Arrow LionHeart
VAD. The majority of these systems utilize transcuta-
neous power transmission and either an integral or
component volume compensatory mechanism. A sec-
ond thrust utilizes a completely new concept of axial
flow technology for chronic support and includes the
Nimbus/TCI HeartMate II, Intracorporeal Ventricular
